AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31774956
Drug: Satralizumab (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Satralizumab (120 mg, subcutaneously at weeks 0, 2, 4, and every 4 weeks thereafter)
Trial: 17202432
Drug: Rotigotine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine (2 mg/24 h titrated to 6 mg/24 h)
Trial: 20887513
Drug: Fluoridin N5®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridin N5® (Fluoride gel; Voco‐GmbH, Cuxhaven, Germany)
Trial: 3995960
Drug: 25 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 micrograms sulprostone gel
Trial: 3569828
Drug: 50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms sulprostone gel
Trial: 3569828
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms sulprostone gel
Trial: 2750356
Drug: gel vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel vehicle tylose
Trial: 17156852
Drug: Poor medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor medication adherence in the 30 days prior to the trial
Trial: 9042987
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg daily (for unhealed or symptomatic patients at week 4)
Trial: 26089641
Drug: Carvedilol sustained-release
RxNorm normalized name: carvedilol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol sustained-release (SR) formulation 8 mg
Trial: 26089641
Drug: Carvedilol sustained-release
RxNorm normalized name: carvedilol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol sustained-release (SR) formulation 16 mg
Trial: 26089641
Drug: Carvedilol sustained-release
RxNorm normalized name: carvedilol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol sustained-release (SR) formulation 32 mg
Trial: 24238498
Drug: Baxter dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baxter dialysis solution 6 L
Trial: 24238498
Drug: Changfu dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changfu dialysis solution 8 L
Trial: 24238498
Drug: Baxter dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baxter dialysis solution 8 L
Trial: 24238498
Drug: Changfu 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changfu 6 L vs 8 L
Trial: 19933719
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment (low to moderate doses)
Trial: 29728515
Drug: End-of-Treatment PET
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End-of-Treatment PET (EoT-PET)
Trial: 26715701
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion analgesia
Trial: 26715701
Drug: Intra-articular infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular infusion analgesia
Trial: 19041835
Drug: Eplerenone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone with standard treatment
Trial: 16439590
Drug: HiPro formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HiPro formula (3.6 g/100 kcal)
Trial: 16439590
Drug: RegPro formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RegPro formula (3.0 g/100 kcal)
Trial: 3900907
Drug: Calf lung
RxNorm normalized name: Calf lung surfactant extract (CLSE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calf lung surfactant extract administered at birth
Trial: 29100885
Drug: Inhaled 21%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled 21% oxygen (placebo) for 2 hours daily, twice weekly, for 12 weeks
Trial: 26471344
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein diet (HP; 1.7 g kg(‐1) per day; n=31)
Trial: 26471344
Drug: Normal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal protein diet (NP; 0.9 g kg(‐1) per day; n=30)
Trial: 12824094
Drug: Theaflavin-enriched green
RxNorm normalized name: theaflavin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theaflavin-enriched green tea extract (375 mg)
Trial: 10638896
Drug: Mivacurium (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium (0.2 mg/kg)
Trial: 6321689
Drug: FACP/weekly doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FACP/weekly doxorubicin
Trial: 30099212
Drug: NLC-based formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLC-based formulations
Trial: 27042735
Drug: Seasonal inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonal inactivated influenza vaccine without a lipid adjuvant
Trial: 24796768
Drug: 0.8 g
RxNorm normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g LT‐02
Trial: 24796768
Drug: 1.6 g
RxNorm normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 g LT‐02
Trial: 24796768
Drug: 3.2 g
RxNorm normalized name: OATMEAL 2.3 g in 113.2 g TOPICAL CREAM [EczeNil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.2 g LT‐02
Trial: 23051558
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg/hydrochlorothiazide 25 mg single-pill combination (T80/H25)
Trial: 15765326
Drug: Morphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.1 mg/kg initial IV injection, then 3 mg every 5 minutes)
Trial: 11510921
Drug: Heparin coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin coated circuits combined with leukocyte filtration (group I)
Trial: 9764623
Drug: oral water
RxNorm normalized name: Oral Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral water
Trial: 30015069
Drug: Multifaceted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifaceted intervention package including detection, treatment, and control of cardiovascular risk factors by nonphysician health workers, free dispensation of combination antihypertensive and cholesterol-lowering medications, and support from a treatment supporter.
Trial: 20711439
Drug: Contrast therapy
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast therapy
Trial: 21470279
Drug: 20% lipid/heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% lipid/heparin infusion (LHI)
Trial: 11106119
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m2 on days 1-8 plus cisplatin 100 mg/m2 (arm A)
Trial: 11106119
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m2 on days 1-8 plus cisplatin 70 mg/m2 (arm B)
Trial: 8225671
Drug: Streptokinase and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase and adjunctive angioplasty
Trial: 6873872
Drug: Intravenous cimetidine
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cimetidine (300 mg)
Trial: 6873872
Drug: Oral cimetidine
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cimetidine (300 mg every 8 hours for 8 days)
Trial: 27321122
Drug: ALA-DAG (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA-DAG (2.5 g/d)
Trial: 8871871
Drug: IFN 5
RxNorm normalized name: cpm/PE/DM/acetaminophen/guaifn 5 mg-10 mg-325 mg-200 mg (day)/2 mg-5 mg-10 mg-325 mg(night) ORAL TABLET, SEQUENTIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN 5 MU, three times weekly by subcutaneous injection alone (n = 14)
Trial: 1799151
Drug: Cefotiam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotiam (2 g intravenously with induction of anaesthesia)
Trial: 6849542
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose corticosteroids (2 g methylprednisolone intravenously once a week plus 0.25 mg/kg prednisone orally daily)
Trial: 6849542
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose corticosteroids (0.25 mg/kg prednisone orally daily)
Trial: 31034349
Drug: In-office bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-office bleaching with high hydrogen peroxide concentration (Opalescence Boost PF 40%, Ultradent) for 40 minutes in three sessions (first, eighth, and 15th days of treatment)
Trial: 31034349
Drug: At-home bleaching
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At-home bleaching with low carbamide peroxide concentration (Opalescence PF 10%, Ultradent) for 60 minutes daily for 15 days
Trial: 25521188
Drug: Dispersible tablet
RxNorm normalized name: Aspirin 75 mg orodispersible tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible tablet
Trial: 16611285
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg b.d., clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. for 7 days
Trial: 8855804
Drug: T enanthate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T enanthate 200 mg im every 20 days
Trial: 6441778
Drug: 3 types
RxNorm normalized name: adenovirus, type 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 types of hypocaloric parenteral nutrition (75 g/day amino acids with different carbohydrates: 120 g dextrose, 120 g or 200 g dextrose/fructose/xylitol)
Trial: 6441778
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving 75 g/day of dextrose
Trial: 19295270
Drug: Oral cavity
RxNorm normalized name: INVEST ANTI-NEOPLASTIC DRUGS LIP,ORAL CAVITY AND PHARYNX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cavity care patient guidance including teaching good brushing methods, O'Leary's Plaque Control Record (PCR) as a cleanliness index, and Eilers' Oral Assessment Guide (OAG) as an overall index after April 2006
Trial: 19295270
Drug: Oral cavity
RxNorm normalized name: INVEST ANTI-NEOPLASTIC DRUGS LIP,ORAL CAVITY AND PHARYNX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cavity care patient guidance
Trial: 9617377
Drug: Optimal antiemetic
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal antiemetic prophylaxis for delayed emesis induced by moderately emetogenic chemotherapy
Trial: 2453704
Drug: Allopurinol 250-500
RxNorm normalized name: allopurinol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 250-500 mg/m2 body surface
Trial: 29653629
Drug: Oral doxycycline
RxNorm normalized name: doxycycline Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxycycline (100 mg once a day for 28 days)
Trial: 306577
Drug: Oral doxycycline
RxNorm normalized name: doxycycline Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxycycline
Trial: 23937708
Drug: Nightly sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nightly sildenafil (50 mg)
Trial: 23937708
Drug: On-demand sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand sildenafil (50 mg)
Trial: 16957147
Drug: Enoxaparin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (0.5 mg/kg)
Trial: 18234466
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (5000 IU)
Trial: 16490582
Drug: Extended-release hydromorphone
RxNorm normalized name: hydromorphone Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release hydromorphone hydrochloride (ER hydromorphone HCl) administered every 24 hours
Trial: 16490582
Drug: Immediate-release hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release hydromorphone hydrochloride (IR hydromorphone HCl) tablets as rescue medication
Trial: 12746764
Drug: Intravenous diphenhydramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diphenhydramine administration
Trial: 12746764
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (L-AMB) infusion
Trial: 10952475
Drug: Zaleplon 20
RxNorm normalized name: Zaleplon
DrugBank: Zaleplon (DB00962)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zaleplon 20 mg alone
Trial: 15496221
Drug: Thioridazine 50
RxNorm normalized name: thioridazine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine 50 mg alone
Trial: 10952475
Drug: Zaleplon 20
RxNorm normalized name: Zaleplon
DrugBank: Zaleplon (DB00962)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zaleplon 20 mg and Thioridazine 50 mg coadministration
Trial: 8337731
Drug: Intramuscular QN
RxNorm normalized name: QN-302
DrugBank: QN-302 (DB18156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular QN alone (quinine dihydrochloride 20 mg salt/kg as a loading dose, followed by 10 mg salt/kg 12 hourly for a total of 6 doses)
Trial: 3806204
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (1-(2-chloroethyl)-1-nitrosourea, vincristine, and prednisone)
Trial: 22360134
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) continuous regimen: 1,000 AU/week for the entire study period (Group 1)
Trial: 8008325
Drug: Azithromycin, 1
RxNorm normalized name: Azithromycin, 1 g oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin, 1 g orally as one dose
Trial: 8008325
Drug: Erythromycin, 500
RxNorm normalized name: Erythromycin, 500 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin, 500 mg orally four times a day for 7 days
Trial: 5015048
Drug: Prednisolone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (20 mg daily for one day before and two days after irradiation)
Trial: 5015048
Drug: No preliminary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preliminary treatment (Control group)
Trial: 22097198
Drug: Cardioplegic solution
RxNorm normalized name: cardioplegic solution no.2
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cardioplegic solution with Salvia miltiorrhizae (SM)
Trial: 22097198
Drug: Cardioplegic solution
RxNorm normalized name: cardioplegic solution no.2
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cardioplegic solution without Salvia miltiorrhizae (Control)
Trial: 19214920
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (CT) with human premixed insulin b.d. (n=20)
Trial: 19214920
Drug: Intensified therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified therapy (ICT) with Lispro at meals and NPH at bedtime (n=24)
Trial: 9817170
Drug: 4-1BB receptor
RxNorm normalized name: PD-L1/4-1BB bispecific antibody
DrugBank: ATG-101 (DB17162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-1BB receptor
Trial: 2780057
Drug: Ketoprofen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (100 mg in 5 ml saline)
Trial: 8942334
Drug: Saline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (5 ml)
Trial: 31689320
Drug: Adhere4U mobile
RxNorm normalized name: CHAMAEMELUM NOBILE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adhere4U mobile medication manager application
Trial: 26573447
Drug: Topical chamomile
RxNorm normalized name: Chamomile
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical chamomile oil, applied twice daily for 4 weeks
Trial: 26573447
Drug: Placebo, applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, applied twice daily for 4 weeks
Trial: 22958202
Drug: Short-acting insulin
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting insulin 4 U
Trial: 14735861
Drug: Intrarectal lidocaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrarectal lidocaine, 20 mg (group 1)
Trial: 8033498
Drug: Orlistat (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (30 to 1200 mg, three times a day for 9 to 10 days)
Trial: 18156658
Drug: Carbohydrate supplementation
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate supplementation (0.25 g.kg(‐1).h(‐1)) during hours 0-12 and 24-36 postexercise
Trial: 15955653
Drug: NonTCA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NonTCA treatment
Trial: 12196838
Drug: Ganciclovir (GCV)
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir (GCV) + Intravenous Immunoglobulin (IVIG)
Trial: 9934915
Drug: Instillation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation of intratracheal surfactant (80 mL/m2)
Trial: 8689457
Drug: hylan G-F
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hylan G-F 20 with NSAID continuation
Trial: 8689457
Drug: hylan G-F
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hylan G-F 20 alone (NSAID discontinuation)
Trial: 375377
Drug: Cimetidine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (0.6 mg.kg‐1h‐1)
Trial: 28633627
Drug: Motivational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motivational intervention (400 patients), delivered by a nurse trained by an expert psychologist, in 32 sessions (1 to 12 fortnightly, 13 to 32 monthly) on top of standard diet and exercise
Trial: 22469604
Drug: Cyclamen europaeum
RxNorm normalized name: Alfalfa/Bogbean/Common Oat/Cyclamen Europaeum/Echinacea angustifoliae/Ginseng, American/Kali Phosphoricum 1 X/7.5 ML-0.3 X/2.5 ML-0.1 X/7.5 ML-0.6 X/2.5 ML-0.1 X/5 ML-0.1 X/5 ML-0.5 C/2.5 ML Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclamen europaeum nasal spray (CE) once daily for 15 days
Trial: 22469604
Drug: Cyclamen europaeum
RxNorm normalized name: Alfalfa/Bogbean/Common Oat/Cyclamen Europaeum/Echinacea angustifoliae/Ginseng, American/Kali Phosphoricum 1 X/7.5 ML-0.3 X/2.5 ML-0.1 X/7.5 ML-0.6 X/2.5 ML-0.1 X/5 ML-0.1 X/5 ML-0.5 C/2.5 ML Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclamen europaeum nasal spray (CE)
Trial: 18075447
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of prednisone for 5 days preoperatively and 9 days postoperatively
Trial: 12361815
Drug: Caspofungin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin (50 mg) intravenously once daily for 7 to 21 days
Trial: 12361815
Drug: Fluconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (200 mg) intravenously once daily for 7 to 21 days
Trial: 6666227
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ISDN sustained-release, three times a day
Trial: 24224808
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with rabeprazole 10 mg b.i.d./q.i.d., amoxicillin 500 mg q.i.d, and sitafloxacin 100 mg b.i.d. (RAS) for 1 week
Trial: 24224808
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with rabeprazole 10 mg b.i.d./q.i.d., amoxicillin 500 mg q.i.d, and sitafloxacin 100 mg b.i.d. (RAS) for 2 weeks
Trial: 24224808
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with rabeprazole 10 mg b.i.d./q.i.d., metronidazole 250 mg b.i.d., and sitafloxacin 100 mg b.i.d. (RMS) for 2 weeks
Trial: 22209180
Drug: Consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of 8 mg dexamethasone
Trial: 15297045
Drug: antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antiretroviral therapy alone
Trial: 9299805
Drug: BIGCBT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIGCBT plus anti-anxiety medication
Trial: 26739717
Drug: KB003 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KB003 (400 mg)
Trial: 24472704
Drug: Quercetin (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (single-dose and repeated intake)
Trial: 20718771
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU; 1000 mg IM)
Trial: 17620637
Drug: Glucantime 60
RxNorm normalized name: Glucantim
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucantime 60 mg/kg intramuscular for 20 days
Trial: 24550171
Drug: Sarilumab 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 100 mg every other week
Trial: 24550171
Drug: Higher sarilumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher sarilumab doses